Key result
Preoperative statin therapy was associated with a reduced risk of 30-day all-cause mortality after primary CABG surgery compared to no therapy (1.80% vs 3.75%; OR 0.53; 95% CI 0.28-0.99; P<0.05).
Why the study?
Does preoperative statin therapy reduce 30-day all-cause mortality in patients undergoing primary CABG surgery with cardiopulmonary bypass?
Population
1,663 patients undergoing primary coronary artery bypass graft surgery with cardiopulmonary bypass between…
Comparison
Preoperative statin therapy vs No preoperative antihyperlipidemic therapy
Design
Cohort
Follow-up
30-day
Authors
Loading...
Supports preoperative statin consideration before primary CABG; leaves open randomized confirmation of mortality benefit.
Cohort (n=1,663)
No
Does preoperative statin therapy reduce 30-day all-cause mortality in patients undergoing primary CABG surgery with cardiopulmonary bypass?
Odds Ratio: 0.53 (95% CI 0.28–0.99)
Absolute Event Rate: 1.8% vs 3.75%
p-value: p=<0.05
Preoperative statin therapy is associated with a roughly 50% reduction in 30-day all-cause mortality following primary CABG surgery with cardiopulmonary bypass.
Pan et al. (2004) conducted a cohort in Primary coronary artery bypass graft (CABG) surgery (n=1,663). Preoperative statin therapy vs. No preoperative antihyperlipidemic therapy was evaluated on 30-day all-cause mortality (OR 0.53, 95% CI 0.28 to 0.99, p=<0.05). Preoperative statin therapy was associated with a reduced risk of 30-day all-cause mortality after primary CABG surgery compared to no therapy (1.80% vs 3.75%; OR 0.53; 95% CI 0.28-0.99; P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: